Outsourcing is coming sooner than later.
With a dead Derm market and too many BCBU that can readily take over Rheum, biosimilars on the horizon, why pay top scale rates to reps to promote an OLD drug that is becoming obsolete.
Face it INBU, you will soon be history
With a dead Derm market and too many BCBU that can readily take over Rheum, biosimilars on the horizon, why pay top scale rates to reps to promote an OLD drug that is becoming obsolete.
Face it INBU, you will soon be history
Without IL 17 , What's next for INBU?
Aucun commentaire:
Enregistrer un commentaire